How is Huntington disease and related disorders diagnosed?

Information about diagnosis is currently limited for this condition.

Are there treatments for Huntington disease and related disorders?

Information about treatment options and management approaches is currently limited for this condition.

What are the complications that can arise from Huntington disease and related disorders?

Currently, there is limited information about specific complications that can arise from Huntington disease and related disorders. However, as the disease progresses, individuals may experience challenges with movement, thinking, and emotional health. Future research may provide more insights into the complications associated with these conditions.

How does Huntington disease and related disorders affect daily life?

Huntington disease and related disorders can impact daily life in various ways, but specific details are currently limited. Individuals may face difficulties with movement, communication, and daily tasks as the disease progresses. Support from family and healthcare providers can help manage these challenges.

What is the prognosis for someone with Huntington disease and related disorders?

Information about the prognosis for Huntington disease and related disorders is currently limited. Generally, the progression of the disease can vary from person to person, and more research is needed to understand long-term outcomes. It's important to discuss individual situations with a healthcare provider for personalized information.

Are there any specific symptoms unique to Huntington disease and related disorders?

At this time, there is limited information about specific symptoms unique to Huntington disease and related disorders. While Huntington disease is known for certain symptoms, the report does not provide detailed descriptions of symptoms for related disorders. Ongoing research may help clarify these aspects in the future.

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Huntington disease and related disorders - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

Huntington disease and related disorders

MONDO:0000167

Overview

A grouping for Huntington disease and similar diseases.

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

GeneReviews

Clinical Guidance

Huntington disease (HD) is a progressive disorder with motor, cognitive, and psychiatric manifestations. The stages of HD can be categorized into premanifest (presymptomatic, prodromal) and manifest (early, moderate, advanced) . The Unified Huntington Disease Rating Scale (UHDRS) is used to assess clinical features in individuals with HD and at risk for HD . The UHDRS is composed of six sections (motor, cognitive, behavioral, functional assessment, independence scale, and total functional capacity [TFC]). The cUHDRS, a composite measure of TFC, cognitive assessment (Stroop Color and Word Test [SCWT], Symbol Digit Modalities Test [SDMT]), and motor function (based on UHDRS total motor score) is the most sensitive measure of progression in HD .

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Suggestive Findings

HD should be suspected in individuals with any of the following clinical and imaging findings and family history.

Clinical findings

Progressive motor disability featuring chorea. Voluntary movement may also be affected.
Mental disturbances including cognitive decline

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for Huntington disease and related disorders. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

Clinical management guidelines for Huntington disease (HD) have been published . Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with HD, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 5. Huntington Disease: Recommended Evaluations Following Initial Diagnosis

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended .

Table 7.

Huntington Disease: Recommended Surveillance

System/Concern | Evaluation | Frequency

Motor

| UHDRS motor assessment1,2 total motor score (TMS) to assess severity of chorea, rigidity, gait abnormalities | At each visit or as indicated

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for Huntington disease and related disorders.

237 publications have been identified in PubMed for Huntington disease and related disorders. Research spans Review / Meta-Analysis (52%), Basic Science / Preclinical (24%), and Epidemiology / Natural History (7%).

Research Type	Count	% of Total
Research summaries	124	52%

Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:39 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

FAQ

Frequently Asked Questions

Common questions about Huntington disease and related disorders

Huntington disease and related disorders is a group that includes Huntington disease and several other similar diseases. This condition is defined by a grouping of these diseases, which may share common features. While the available information is limited, it is clear that this grouping aims to bring together conditions that have similarities to Huntington disease. More detailed information on how these diseases affect individuals may be provided in future research and updates.

Information about symptoms is currently limited for this condition.

Information about causes, genetics, and risk factors is currently limited for this condition. Associated genes include HTT.

← Back to All Diseases

GeneReviews

Differential Diagnosis

Huntington disease (HD) falls into the differential diagnosis of chorea, dementia, and psychiatric disturbances . Individuals with these features and a family history suggestive of autosomal dominant inheritance who do not have an abnormal CAG repeat expansion in HTT are described as having an HD phenocopy. Genetic disorders characterized by phenotypes overlapping that of HD are summarized in and reviewed elsewhere (see and ). Juvenile HD. The diagnosis of HD in children is apparent in a family with a history of HD in which the father is the transmitting parent. In an affected individual with no known family history of HD and no abnormal CAG repeat length in HTT, ataxia-telangiectasia , pantothenate kinase-associated neurodegeneration, Lesch-Nyhan disease , Wilson disease , progressive myoclonic epilepsy , and other metabolic diseases must be excluded. Table 4. Huntington Disease: Differential Diagnosis

Gene(s)	Disorder	MOI	Features of Disorder
ADCY5	ADCY5-related movement disorder1	ADAR2	Dystonia; Chorea
ATN1	DRPLA (dentatorubral-pallidoluysian atrophy)	AD	Dystonia; Chorea; Cognitive impairment; Psychiatric manifestations
ATXN3	Spinocerebellar ataxia type 1 (SCA1), SCA2, SCA3	AD	Gait disturbances; Progressive motor decline; Cognitive impairment; Psychiatric manifestations
Tremor ATXN8OS/ATXN8	Spinocerebellar ataxia type 83	AD	Dystonia; Cognitive impairment; Chorea; Oculomotor disturbances
C9orf72	C9orf72 frontotemporal dementia /or amyotrophic lateral sclerosis4	AD	Dementia; Psychiatric manifestations; Dystonia
FTL	Neuroferritinopathy (NBIA3)	AD	Chorea; Dystonia
FXN	Late-onset Friedreich ataxia	AR	Dysarthria; Gait disturbances
Primary familial brain calcification	ADAR	Chorea; Gait dysfunction; Dystonia; Speech disturbance; Neurobehavioral manifestations	Choreoathetosis; Tremor JPH3
Huntington disease-like 2	AD	Clinically indistinguishable from HD	Described exclusively in persons w/confirmed or likely African ancestry MAPT
MAPT-related frontotemporal dementia	AD	Late onset (mean age of onset is 49.5 yrs); Progressive changes in motor function memory; Behavioral psychiatric manifestations	—
Not assoc w/chorea NKX2-1(TITF1)	Benign hereditary chorea (See NKX2-1-Related Disorders.)	AD	Chorea

Source: GeneReviews — "Huntington Disease"

System/Concern	Evaluation	Comment
Genetic counseling	By genetics professionals1	To obtain a pedigree inform affected persons their families re nature, MOI, implications of HD to facilitate medical personal decision making Psychosocial support resources; Note: Children adolescents living w/a parent w/HD, sometimes in very deprived conditions, can have special challenges.
Huntington Disease: Treatment of Manifestations Manifestation/Concern	Treatment	Considerations/Other
Chorea	Pharmacologic	Typical (sulpiride) atypical (olanzapine, risperidone, quetiapine, aripiprazole) neuroleptics may partially suppress chorea; Benzodiazepines
Hypokinesia rigidity	Pharmacologic	Tizanidine, baclofen, botulinum toxin injections for muscle spasms; Anti-parkinsonian agents may be helpful (specifically in juvenile HD).
Myoclonic hyperkinesia	Sodium valproate or levetiracetam	Useful for significant isolated myoclonus
Psychiatric manifestations	Pharmacologic	SSRIs (e.g., paroxetine, fluoxetine, citalopram, sertraline) for depression anxiety; Other drugs w/serotonergic noradrenergic effects (e.g.

Latest News & Developments

1 recent

View all

AI-curated news mentioning Huntington disease and related disorders

Updated May 22, 2026

Treatment & Clinical News•

Pipeline & Approvals

•4 months ago(May 22)

Pharming gains EU approval for Joenja, first APDS therapy | PHARM Stock News

EU approval makes Joenja the first and only approved APDS treatment across the EU, Norway, Iceland and Liechtenstein, with Germany launch due in Q3 2026. Leniolisib is also being evaluated in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The EU approval advances Pharming’s global rare disease expansion strategy for Joenja. According to Pharming, Joenja already has approvals in the United States, United Kingdom, Japan, Australia and Israel, and the new European authorization further broadens its international treatment footprint for APDS. ... May 7, 2026 Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders Pharming (PHARM) received European Commission marketing authorization for Joenja (leniolisib), the first and only approved treatment in the EU for activated PI3K delta syndrome (APDS) in patients aged 12 and older. First EU launch is expected in Germany in Q3 2026, with further roll-out after national reimbursement decisions. The approval, based on a Phase II/III trial and long-term extension data, is valid in all 27 EU states plus Norway, Iceland and Liechtenstein, and supports Pharming’s rare disease expansion alongside existing approvals in the US, UK, Japan, Australia and Israel. Investors watch these conditions because they create steady, long‑term demand for diagnostics and specialized treatments (including replacement therapies and gene therapies); successful clinical trials or approvals can rapidly change a company’s revenue outlook and valuation, similar to discovering a cure for a chronic condition that many patients need.

View all news for Huntington disease and related disorders

Kisho

Huntington disease and related disorders

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Motor

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Establishing the Diagnosis

Differential Diagnosis

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Cognition

Functional capacity

Recent Publications

Latest News & Developments

Pharming gains EU approval for Joenja, first APDS therapy | PHARM Stock News

Huntington disease and related disorders

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Motor

Research Landscape

Medical References

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is Huntington disease and related disorders?

What are the symptoms of Huntington disease and related disorders?

What causes Huntington disease and related disorders?

How is Huntington disease and related disorders diagnosed?

Are there treatments for Huntington disease and related disorders?

What are the complications that can arise from Huntington disease and related disorders?

How does Huntington disease and related disorders affect daily life?

What is the prognosis for someone with Huntington disease and related disorders?

Are there any specific symptoms unique to Huntington disease and related disorders?

Establishing the Diagnosis

Differential Diagnosis

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Cognition

Functional capacity

Recent Publications

Latest News & Developments

Pharming gains EU approval for Joenja, first APDS therapy | PHARM Stock News